Background: in patients with multiple myeloma there is a raised level of a protein, named M-protein. This M-protein is normally used to monitor disease status and evaluate response to treatment, as a decrease in M-protein is taken as evidence of therapeutic efficacy. However, the M-protein has a long half life in serum, approximately three weeks, which tend to be a practical problem, since the investigators can first determine hereafter if the treatment is effective. A new assay has the possibility only to measure part of this protein, namely "the light chains", which also is measured in a blood sample. The half life of these light chains is much shorter, namely 2-6 hours. In theory, this means a more rapid measure of the effect of a given treatment, thereby being able to determine earlier if the treatment should continue or changed to another strategy. Purpose: the purpose of this study is to evaluate the clinical value of the use of the serum free light chain (sFLC) assay in comparison to the M-protein in monitoring patients under treatment for multiple myeloma. Method: the investigators measure sFLC in patients receiving there 1st treatment, either at the time of diagnosis or in the relapse setting. sFLC is measured on a regular basis, and the results are compared to the M-protein.
Study Type
OBSERVATIONAL
Enrollment
30
Department of Haematology, research unit
Odense C, Denmark
RECRUITINGTime to 50% reduction in the concentration of the abnormal serum free light chain compared to 50% reduction in M-protein
Time frame: 1, 2, 3, 4 and 5 days, 2, 3 and 6 weeks after therapy,
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.